Analyst Upgrades: Amazon, TherapeuticsMD, and Marriott

Analysts upwardly revised their ratings and price targets on Amazon.com, Inc. (NASDAQ:AMZN), TherapeuticsMD Inc (NYSEMKT:TXMD), and Marriott International Inc (NASDAQ:MAR)

by Josh Selway

Published on Dec 8, 2015 at 9:19 AM
Updated on Jul 20, 2020 at 3:23 PM

Analysts are weighing in on e-tailer Amazon.com, Inc. (NASDAQ:AMZN), women's health issue TherapeuticsMD Inc (NYSEMKT:TXMD), and hotelier Marriott International Inc (NASDAQ:MAR). Here's a quick roundup of today's bullish brokerage notes on AMZN, TXMD, and MAR. 

  • AMZN is positioned 1.1% lower ahead of the open, despite some high praise from Pacific Crest. The firm gave the stock a "buy" rating, even though it's already more than doubled in 2015, while setting its price target at $800 -- a roughly 19% premium to Monday's close at $669.83, and in uncharted territory. More broadly, the analysts said "e-commerce can be at least 30% of total retail sales in the next five years," compared to 7% currently. Pacific Crest certainly isn't alone in its bullish outlook, with 82% of all other brokerage firms calling Amazon.com, Inc. a "buy" or better. Option traders, though, are much more bearish. AMZN's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands at 1.05, higher than 84% of all other readings from the past year. This points to a stronger-than-usual preference for put buying compared to call buying
  • TXMD is set to shoot close to 40% higher at the open, after the company announced positive top-line results for its dyspareunia treatment, TX-004HR, in a late-stage study. The security has since received three price-target increases, with Guggenheim setting the bar the highest at $33 -- a dramatic move, considering the shares closed Monday at $6.53. What's more, it's been a disappointing few months for TherapeuticsMD Inc, which has shed 26.1% since its late-July annual high of $8.83. This underperformance has brought in the short sellers. Over 18% of TXMD's float is sold short, accounting for an astonishing 26 days' worth of buying power, at the stock's normal daily volumes. 
  • MAR will look to use some bullish attention from Berenberg to make up some of its 10.9% year-to-date decline. The brokerage firm started the security with a "buy" rating and a $90 price target -- which would mark a record high -- while adding Marriott International Inc to its "Alpha List." If the shares do rally, speculators could be in for some pain. MAR's Schaeffer's put/call open interest ratio (SOIR) stands at 3.16, which outranks 89% of all other readings from the past year. Put simply, short-term option traders are much more put-skewed than normal. MAR settled at $69.50 on Monday. 
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter